Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 9/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104005 | 0.70 | CES2 (1.00) | CES2L3MBTL1KDM4ERAB9A | |
| SCHEMBL12857443 | 0.69 | PTGS1 (1.00) | PTGS1PTGS2L3MBTL1KDM4ERAB9A | |
| SCHEMBL19499378 | 0.65 | CES2 (0.89) | CES2L3MBTL1KDM4ERAB9AMEN1 | |
| SCHEMBL4240299 | 0.65 | CES2 (0.76) | CES2L3MBTL1KDM4ERAB9AKMT2A | |
| SCHEMBL4059748 | 0.65 | CES2 (0.82) | CES2L3MBTL1KDM4ERAB9A | |
| SCHEMBL12857341 | 0.63 | KAT8 (0.51) | PTGS1PTGS2L3MBTL1KDM4ECYP2C19 | |
| SCHEMBL23607612 | 0.62 | GAA (0.71) | CES2L3MBTL1KDM4ERAB9AMEN1 | |
| Dihydrochalcone SCHEMBL29359372 | 0.59 | CYP19A1 (0.80) | KDM4ERAB9ATSHRTDP1 | |
| SCHEMBL4435666 | 0.59 | KMT2A (0.72) | CES2L3MBTL1KDM4EMEN1KMT2A | |
| Dihydrochalcone SCHEMBL2827303 | 0.59 | CYP19A1 (0.80) | KDM4ERAB9ATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | CES2 4799/4885PTGS1 633/4885PTGS2 980/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | CES2 4799/4885PTGS1 633/4885PTGS2 980/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | CES2 4799/4885PTGS1 633/4885PTGS2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.